We HALF to Talk | Half to Talk TNBC

For patients with mTNBC,
time is limited

^†34% (n=679) did not survive beyond 1L, 10% (n=192) had no evidence of treatment after 1L, and 5% (n=103) received a 2L treatment but were censored. Real-world study published in 2025 of patients diagnosed with previously untreated mTNBC (n=2004) from 2011 to 2022 at approximately 280 cancer clinics in the US. Population included patients who received single-agent chemotherapy, combination chemotherapy, an anti–PD-1 or anti–PD-L1 agent regimen, a PARPi regimen, or other therapy in the 1L setting.¹

mTNBC has the lowest
5-year survival rate of any metastatic breast cancer subtype

5-year survival rate by metastatic breast cancer subtype²

A woman standing and staring straight into the distance. Actor portrayal.

As patients progress past first line, they are less likely to achieve benefit from each subsequent line of mTNBC treatment^3-6

1L mPFS: 5.6-7.5 mo; 2L + mPFS: 1.5-2.8 mo

First line is the best opportunity to delay progression^3-6

We have to do more.

Half of mTNBC patients may have only one chance at treatment

At Gilead, we support research and development committed to elevating the standard of care for patients with metastatic triple-negative breast cancer (mTNBC).

Add your name to the list of people committed to advancing research in mTNBC and get the latest information from us.

Fields marked with * are required.

First name

Last name

Email address Confirm email address

Role or function that best fits your position

Practice ZIP code (Optional)

NPI number (Optional)

Terms and Conditions*

Gilead respects the privacy of your personal information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or information materials. Gilead, and companies providing services to Gilead, will not sell or rent your personally identifiable information. Review Gilead’s Privacy Statements for more information.

I agree to the Terms and Conditions. I certify that I am a US healthcare professional.

1L=first-line; 2L=second-line; 3L+=third-line or later; HER2=human epidermal growth factor receptor 2; HR=hormone receptor; mBC=metastatic breast cancer; mTNBC=metastatic triple-negative breast cancer; PFS=progression-free survival.

References:

Punie K, Kurian AW, Ntalla I, et al. Oncologist. 2025;30(3):oyaf034. doi:10.1093/oncolo/oyaf034
Surveillance, Epidemiology, and End Results Program (SEER). National Cancer Institute. 2025. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
Cortes J, Rugo HS, Cescon DW, et al. N Engl J Med. 2022;387(3):217-229. doi:10.1056/NEJM0a2202809
O’Shaughnessy J, Punie K, Oliveira M, et al. Poster presented at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021.
Carey LA, Loirat D, Punie K, et al. Poster presented at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021.
Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Ann Oncol. 2016;27(8):1525-1531. doi:10.1093/annonc/mdw203

TOP

This site is intended for US healthcare professionals

Because half of patients (49%) with mTNBC never receive second-line therapy1*

For patients with mTNBC, time is limited

mTNBC has the lowest 5-year survival rate of any metastatic breast cancer subtype

5-year survival rate by metastatic breast cancer subtype2

As patients progress past first line, they are less likely to achieve benefit from each subsequent line of mTNBC treatment3-6

First line is the best opportunity to delay progression3-6